NEW YORK (GenomeWeb News) – Linguamatics today said that the diabetes care company Novo Nordisk will use its text mining and natural language processing software.
Under a multi-year agreement, the Cambridge, UK-based company said that Novo Nordisk will use its I2E to mine published literature and internal information sources to provide intelligence for making research and development decisions. Linguamatics COO Roger Hale said in a statement that the I2E platform can be used to "deliver value for questions ranging from R&D to business and competitor intelligence."
The software is used for a variety of applications, including in biomarker discovery, pharmacogenomics, target selection, systems biology, and toxicology.
Financial terms of the agreement were not disclosed.